Nanobiotix S.A./€NANO
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Nanobiotix S.A.
Nanobiotix S.A. is a biotechnology company focusing on developing innovative nanomedicine solutions for cancer therapy. Its core business is centered around the development of NBTXR3, a radioenhancer designed to increase the efficacy of radiotherapy in cancer treatment. Founded in 2003, Nanobiotix is headquartered in Paris, France. Its strategic positioning lies in its proprietary nanotechnology platform, which aims to address unmet needs in oncology by potentially improving outcomes and safety for patients undergoing radiotherapy. The company operates primarily within the European and U.S. markets, with ongoing clinical trials to expand its therapeutic applications.
Ticker
€NANO
Sector
Primary listing
PAR
Industry
Biotechnology
Headquarters
Employees
108
Website
Nanobiotix S.A. Metrics
BasicAdvanced
€287M
-
-€1.44
1.55
-
Price and volume
Market cap
€287M
Beta
1.55
52-week high
€6.13
52-week low
€2.62
Average daily volume
109K
Financial strength
Current ratio
1.043
Quick ratio
0.977
Long term debt to equity
-69.977
Total debt to equity
-77.472
Interest coverage (TTM)
-8.44%
Profitability
EBITDA (TTM)
-67.666
Gross margin (TTM)
100.00%
Net profit margin (TTM)
947.59%
Operating margin (TTM)
949.35%
Effective tax rate (TTM)
-0.15%
Revenue per employee (TTM)
-€70,000
Management effectiveness
Return on assets (TTM)
-52.89%
Return on equity (TTM)
201.73%
Valuation
Price to revenue (TTM)
-39.771
Price to book
-4.37
Price to tangible book (TTM)
-4.36
Price to free cash flow (TTM)
-14.018
Free cash flow yield (TTM)
-7.13%
Free cash flow per share (TTM)
-0.432
Growth
Revenue change (TTM)
-119.86%
Earnings per share change (TTM)
33.47%
3-year revenue growth (CAGR)
39.53%
10-year revenue growth (CAGR)
10.01%
3-year earnings per share growth (CAGR)
2.08%
10-year earnings per share growth (CAGR)
6.86%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Nanobiotix S.A. stock?
Nanobiotix S.A. (NANO) has a market cap of €287M as of July 30, 2025.
What is the P/E ratio for Nanobiotix S.A. stock?
The price to earnings (P/E) ratio for Nanobiotix S.A. (NANO) stock is 0 as of July 30, 2025.
Does Nanobiotix S.A. stock pay dividends?
No, Nanobiotix S.A. (NANO) stock does not pay dividends to its shareholders as of July 30, 2025.
When is the next Nanobiotix S.A. dividend payment date?
Nanobiotix S.A. (NANO) stock does not pay dividends to its shareholders.
What is the beta indicator for Nanobiotix S.A.?
Nanobiotix S.A. (NANO) has a beta rating of 1.55. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.